NASDAQ:CODX Co-Diagnostics (CODX) Stock Price, News & Analysis $0.32 +0.01 (+3.91%) Closing price 04:00 PM EasternExtended Trading$0.31 0.00 (-1.54%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Co-Diagnostics Stock (NASDAQ:CODX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Co-Diagnostics alerts:Sign Up Key Stats Today's Range$0.30▼$0.3450-Day Range$0.25▼$0.3252-Week Range$0.23▼$2.23Volume1.25 million shsAverage Volume5.37 million shsMarket Capitalization$12.28 millionP/E RatioN/ADividend YieldN/APrice Target$5.50Consensus RatingBuy Company Overview Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah. Read More Co-Diagnostics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks89th Percentile Overall ScoreCODX MarketRank™: Co-Diagnostics scored higher than 89% of companies evaluated by MarketBeat, and ranked 131st out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCo-Diagnostics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCo-Diagnostics has only been the subject of 1 research reports in the past 90 days.Read more about Co-Diagnostics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Co-Diagnostics are expected to grow in the coming year, from ($1.22) to ($1.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Co-Diagnostics is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Co-Diagnostics is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCo-Diagnostics has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Co-Diagnostics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.94% of the float of Co-Diagnostics has been sold short.Short Interest Ratio / Days to CoverCo-Diagnostics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Co-Diagnostics has recently decreased by 29.27%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCo-Diagnostics does not currently pay a dividend.Dividend GrowthCo-Diagnostics does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.10 Percentage of Shares Shorted1.94% of the float of Co-Diagnostics has been sold short.Short Interest Ratio / Days to CoverCo-Diagnostics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Co-Diagnostics has recently decreased by 29.27%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment-0.63 News SentimentCo-Diagnostics has a news sentiment score of -0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Co-Diagnostics this week, compared to 1 article on an average week.Search Interest6 people have searched for CODX on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat Follows2 people have added Co-Diagnostics to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Co-Diagnostics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.40% of the stock of Co-Diagnostics is held by insiders.Percentage Held by InstitutionsOnly 14.99% of the stock of Co-Diagnostics is held by institutions.Read more about Co-Diagnostics' insider trading history. Receive CODX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Co-Diagnostics and its competitors with MarketBeat's FREE daily newsletter. Email Address CODX Stock News HeadlinesCo-Diagnostics, Inc. (NASDAQ:CODX) Short Interest UpdateAugust 22 at 2:53 AM | americanbankingnews.comReviewing Bausch + Lomb (NYSE:BLCO) & Co-Diagnostics (NASDAQ:CODX)August 20 at 4:05 AM | americanbankingnews.comElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a new AI supercomputer—what one industry CEO calls “the most powerful in the world.” Musk says this tech will drive the next wave of American innovation. You can’t invest in the supercomputer directly—but there’s a backdoor way to access the company powering it. It’s smaller than Tesla or Nvidia, but both rely on it for future growth.August 22 at 2:00 AM | Paradigm Press (Ad)Co-Diagnostics, Inc. to Host Booth at 17th Next Generation Dx Summit in Washington, D.C. ...August 18, 2025 | gurufocus.comCo-Diagnostics, Inc. to Host Booth at 17th Next Generation Dx Summit in Washington, D.C.August 18, 2025 | gurufocus.comCo-Diagnostics, Inc. to Host Booth at 17th Next Generation Dx Summit in Washington, D.C.August 18, 2025 | prnewswire.comD. Boral Capital Reiterates "Buy" Rating for Co-Diagnostics (NASDAQ:CODX)August 17, 2025 | americanbankingnews.comCo-Diagnostics, Inc. (CODX) Q2 2025 Earnings Conference Call TranscriptAugust 14, 2025 | seekingalpha.comSee More Headlines CODX Stock Analysis - Frequently Asked Questions How have CODX shares performed this year? Co-Diagnostics' stock was trading at $0.75 at the start of the year. Since then, CODX stock has decreased by 57.5% and is now trading at $0.3189. How were Co-Diagnostics' earnings last quarter? Co-Diagnostics, Inc. (NASDAQ:CODX) announced its earnings results on Thursday, August, 14th. The company reported ($0.23) earnings per share for the quarter, topping analysts' consensus estimates of ($0.25) by $0.02. The company had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.30 million. Co-Diagnostics had a negative trailing twelve-month return on equity of 69.49% and a negative net margin of 3,588.33%. Read the conference call transcript. When did Co-Diagnostics IPO? Co-Diagnostics (CODX) raised $9 million in an initial public offering on Thursday, July 13th 2017. The company issued 1,300,000 shares at $6.35-$6.75 per share. WallachBeth Capital and Network 1 Securities acted as the underwriters for the IPO. Who are Co-Diagnostics' major shareholders? Top institutional investors of Co-Diagnostics include Jane Street Group LLC (0.50%). View institutional ownership trends. How do I buy shares of Co-Diagnostics? Shares of CODX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Co-Diagnostics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Co-Diagnostics investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Moderna (MRNA), Inovio Pharmaceuticals (INO) and Novavax (NVAX). Company Calendar Last Earnings8/14/2025Today8/22/2025Next Earnings (Estimated)11/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Services Sub-IndustryMedical Equipment Current SymbolNASDAQ:CODX CIK1692415 Webwww.codiagnostics.com Phone(801) 438-1036FaxN/AEmployees100Year Founded2013Price Target and Rating Average Price Target for Co-Diagnostics$5.50 High Price Target$10.00 Low Price Target$1.00 Potential Upside/Downside+1,624.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$37.64 million Net Margins-3,588.33% Pretax Margin-3,584.55% Return on Equity-69.49% Return on Assets-60.49% Debt Debt-to-Equity RatioN/A Current Ratio4.12 Quick Ratio4.23 Sales & Book Value Annual Sales$3.91 million Price / Sales3.14 Cash FlowN/A Price / Cash FlowN/A Book Value$1.07 per share Price / Book0.30Miscellaneous Outstanding Shares38,520,000Free Float35,288,000Market Cap$12.28 million OptionableOptionable Beta0.51 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:CODX) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Co-Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Co-Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.